7 active not recruiting, 4 recruiting, 2 completed, 2 terminated. 10 Phase 2, 4 Phase 1, 2 Not applicable, 2 Phase 3.
Follow Stage III Colon Cancer AJCC v8: new trials by email Literature Review of Stage III Colon Cancer AJCC v8 trials Research Report on Stage III Colon Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment Zanidatamab, Resection, Patient Observation - Colon Carcinoma, Colorectal Carcinoma | Phase 2 | Recruiting | Emory University | 38 | 2026-04-07 | 2026-04-17 |
| Family Communications After Genetic Testing Biospecimen Collection, Genetic Testing, Communication Intervention - Colon Adenocarcinoma, Colorectal Adenocarcinoma | Not applicable | Recruiting | Alliance for Clinical Trials in Oncology | 4186 | 2026-04-06 | 2026-10-02 |
| Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer Biopsy Procedure, Biospecimen Collection, Colonoscopy - Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 | Phase 2 | Recruiting | Emory University | 40 | 2025-09-19 | 2026-10-02 |
| Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer Balstilimab, Biopsy, Biospecimen Collection - Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma | Phase 2 | Withdrawn | City of Hope Medical Center | 2024-11-01 | 2024-11-21 | |
| Designing a Dyad-Based mHealth Intervention to Improve Adherence to Lifestyle Recommendations in Colorectal Cancer Survivors and Their Family Caregivers Discussion, Educational Activity, Internet-Based Intervention - Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8 | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 70 | 2024-05-03 | 2026-04-09 |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Encorafenib, Cetuximab, Biospecimen Collection - Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1 | 2023-08-16 | 2026-07-02 |
| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation Cetuximab, Encorafenib, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 86 | 2022-07-19 | 2026-07-08 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial CXCR1/2 Inhibitor SX-682, Nivolumab - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 51 | 2020-10-14 | 2026-07-20 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer Ipilimumab, Nivolumab, Regorafenib - Advanced Colon Adenocarcinoma, Metastatic Colon Adenocarcinoma | Phase 1 | Completed | City of Hope Medical Center | 39 | 2020-05-27 | 2026-01-28 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer Panitumumab, Quality-of-Life Assessment, Questionnaire Administration - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 2 | Unknown | Academic and Community Cancer Research United | 12 | 2020-04-24 | 2024-05-21 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial Genetic Testing - Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma | Terminated | Academic and Community Cancer Research United | 199 | 2020-04-20 | 2025-08-29 | |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 42 | 2019-12-27 | 2026-02-10 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer Savolitinib - Colorectal Carcinoma, Metastatic Colon Adenocarcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-07-25 | 2023-10-17 |
| Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment Quality-of-Life Assessment, Questionnaire Administration - Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 565 | 2018-06-11 | 2026-09-25 | |
| Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair Atezolizumab, Biospecimen Collection, Computed Tomography - Colon Adenocarcinoma, DNA Repair Disorder | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 712 | 2017-10-16 | 2026-10-22 |
Colonic Neoplasms (17) · Rectal Neoplasms (13) · Colorectal Neoplasms (10) · Breast Neoplasms (1) · Carcinosarcoma (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · DNA Repair-Deficiency Disorders (1) · Endometrial Neoplasms (1) · Neoplasm Metastasis (1) · Salivary Gland Neoplasms (1) · Stomach Neoplasms (1)
Colonic Diseases (17) · Digestive System Diseases (17) · Digestive System Neoplasms (17) · Gastrointestinal Diseases (17) · Gastrointestinal Neoplasms (17) · Intestinal Diseases (17) · Intestinal Neoplasms (17) · Neoplasms (17) · Neoplasms by Site (17) · Rectal Diseases (14) · Colorectal Neoplasms (7) · Breast Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · Biopsy (4) · Cetuximab (3) · Nivolumab (3) · regorafenib (3) · Genetic Testing (2) · Trifluridine (2) · Watchful Waiting (2) · encorafenib (2) · trifluridine tipiracil drug combination (2) · (225)Ac-DOTA-c(RGDyK) (1) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Bevacizumab (1) · CTLA-4 Antigen (1)
National Cancer Institute (NCI) (4) · Academic and Community Cancer Research United (2) · Alliance for Clinical Trials in Oncology (2) · City of Hope Medical Center (2) · Emory University (2) · M.D. Anderson Cancer Center (2) · ECOG-ACRIN Cancer Research Group (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1)
United States (16) · Puerto Rico (3) · Germany (1)
John H Strickler (3) · Frank A Sinicrope (2) · Marwan G Fakih (2) · Alisha Bent, MD (1) · Christine M Parseghian, MD (1) · Christos Fountzilas, MD (1) · Kanwal P Raghav (1) · Olumide B. Gbolahan, MBBS, MSc (1) · Oluwadunni E. Emiloju, MBBS, MS (1) · Roberto M Benzo, PhD (1) · Sheetal Kircher (1) · Van K Morris (1)
PMID 36892833, PMID 38194233, PMID 39244627, PMID 39287948, PMID 39652198, PMID 40953502, PMID 41880612
P30CA015083 (2), P30CA138292 (2), P30CA033572 (1), R01CA187238 (1), U10CA180820 (1), U10CA180821 (1), U10CA180888 (1), UG1CA189828 (1), UM1CA186688 (1), UM1CA186704 (1)